Key Highlights

  • Sionna Therapeutics' Phase 2a PreciSION CF trial of SION-719 failed to meet its primary sweat chloride endpoint.
  • The placebo-adjusted difference was only -1.0 mmol/L.
  • The company has terminated the SION-719 add-on program.
  • Sionna remains well-capitalized with $268.3 million in cash.

Sionna Therapeutics ( Nasdaq : SION) announced that its Phase 2a PreciSION CF trial of SION-719 as an add-on to Trikafta failed to meet the primary sweat chloride endpoint, showing only a -1.0 mmol/L placebo-adjusted difference.

What Happened

This result led to the termination of the SION-719 add-on program. The company remains well-capitalized with $268.3 million in cash and is currently evaluating future development for its SION-451 dual-combination therapy.

A -1.0 mmol/L placebo-adjusted difference in sweat chloride, the standard biomarker used to assess CFTR modulator efficacy in cystic fibrosis, falls well short of the threshold typically needed to demonstrate a clinically meaningful additive benefit on top of existing background therapy.

Market Reaction

The disclosed information does not include stock price or trading data for Sionna Therapeutics following the trial result and program termination.

The substantial cash position gives the company flexibility to redirect resources toward its remaining pipeline without an immediate need for external financing, even after absorbing the setback from the discontinued program.

Outlook

The company's evaluation of future development plans for SION-451 represents the next disclosed milestone for its cystic fibrosis pipeline, supported by its $268.3 million cash position.